SCHEMBL10244428

SCHEMBL10244428

COC(=O)NCCNC(C)c1ccc(OC)c(CN2CCOCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 5/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 3/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
KCNJ1 P48048 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 1/20 0.42
PAX8 Q06710 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243930 0.91 L3MBTL1 (0.50) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL10243726 0.90 L3MBTL1 (0.52) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL335840 0.84 HTT (0.44) ALDH1A1KDM4EMAPTLMNARECQL
SCHEMBL10243900 0.82 S1PR1 (0.44) ALDH1A1KDM4EMAPTLMNARECQL
SCHEMBL10244421 0.78 CACNA1B (0.52) ALDH1A1LMNAKMT2AGAAMEN1
SCHEMBL10243926 0.77 PKM (0.46) ALDH1A1LMNACYP2D6CYP2C9
SCHEMBL10244408 0.75 PAX8 (0.43) ALDH1A1KDM4EMAPTLMNAKMT2A
SCHEMBL335108 0.74 KDM4E (0.51) ALDH1A1KDM4EMAPTLMNAKMT2A
SCHEMBL10244323 0.73 SLC22A3 (0.51) LMNAGAA
SCHEMBL336028 0.73 KDM4E (0.53) ALDH1A1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885KDM4E 128/4885MAPT 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.